Molecular Signature of Monocytes Shaped by the Shigella sonnei 1790-Generalized Modules for Membrane Antigens Vaccine

Int J Mol Sci. 2024 Jan 17;25(2):1116. doi: 10.3390/ijms25021116.

Abstract

Shigellosis, an acute gastroenteritis infection caused by Shigella species, remains a public health burden in developing countries. Recently, many outbreaks due to Shigella sonnei multidrug-resistant strains have been reported in high-income countries, and the lack of an effective vaccine represents a major hurdle to counteract this bacterial pathogen. Vaccine candidates against Shigella sonnei are under clinical development, including a Generalized Modules for Membrane Antigens (GMMA)-based vaccine. The mechanisms by which GMMA-based vaccines interact and activate human immune cells remain elusive. Our previous study provided the first evidence that both adaptive and innate immune cells are targeted and functionally shaped by the GMMA-based vaccine. Here, flow cytometry and confocal microscopy analysis allowed us to identify monocytes as the main target population interacting with the S. sonnei 1790-GMMA vaccine on human peripheral blood. In addition, transcriptomic analysis of this cell population revealed a molecular signature induced by 1790-GMMA mostly correlated with the inflammatory response and cytokine-induced processes. This also impacts the expression of genes associated with macrophages' differentiation and T cell regulation, suggesting a dual function for this vaccine platform both as an antigen carrier and as a regulator of immune cell activation and differentiation.

Keywords: Generalized Modules for Membrane Antigens (GMMA); Shigella sonnei; immunity; monocytes; transcriptomics; vaccine.

MeSH terms

  • Antigens, Bacterial / genetics
  • Blood Group Antigens*
  • Gastroenteritis*
  • Humans
  • Methylmethacrylates*
  • Monocytes
  • Shigella sonnei / genetics
  • Vaccines*

Substances

  • glyceryl methyl methacrylate
  • Antigens, Bacterial
  • Vaccines
  • Blood Group Antigens
  • Methylmethacrylates

Grants and funding

This work was entirely sponsored by GlaxoSmithKline Biologicals SA. GSK was also responsible for all costs incurred by publishing.